Day 213: DVAX Thumbs Up

Mother's Little Helper portfolio was UP today +$2,799.84 (-0.37%).

Overall GAIN YTD: +$174,661.32 (+29.91%).

According to CNN Money our benchmark index, the S&P 500 is up +10.42% Year To Date.

http://money.cnn.com/data/markets/sandp/

Dynavax technologies had a big win today when they received approval from the advisory committee for Heplisav-B. Heplisav-B will now move on and seek formal FDA approval on or before August 10th. The FDA typically approves a drug that the AdComm Dynavax closed today at $9.25/share and is up about 80% right now in after hours trading at about $16.65. DVAX has been a solid performer for the portfolio. With our cost basis at

$4.10/share, a $16 share price will give us approximately a 290% return on the initial investment. Dynavax shares should see additional appreciation as Heplisav-B is commercialized and as their SD-101 oncology drug comes up for possible approval this summer.

Stay Invested,

Clay Baker

Disclosure: I am personally invested long in these stocks that appear in the MLH portfolio and may purchase or sell share withing the next 72 hours. I am also invested in other stocks that do not appear in the MLH portfolio: BA, BRK.B, CELG, CSCO, CTXS, CVX, DOW, DVAX, FB, IBM, NTES, NVDA, OMER, PFE, PG, RDHL, SCHW, THO, TWX, VEEV, VZ, XLNX, XOM

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.This article is not intended to offer investing advice, guarantee 100% accurate predictions, or to be interpreted as providing a personal recommendation.